Acorda Therapeutics Inc. won a second victory against hedge fund manager Kyle Bass but it is waiting for a district court ruling on the validity of five patents covering its multiple sclerosis drug Ampyra (dalfampridine). The outcome will determine if it will be free from generic competition until 2025.
In a March 9 final written decision, the US Patent and Trademark Office's Patent Trial and Appeal Board...





